A Three-part, Randomized Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy, Young Subjects and Elderly Subjects

Trial Profile

A Three-part, Randomized Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy, Young Subjects and Elderly Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs BC 007 (Primary)
  • Indications Dilated cardiomyopathy
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Berlin Cures
  • Most Recent Events

    • 17 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 May 2018.
    • 17 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
    • 21 Jun 2017 Study has changed from part two to part three,and dose of drug has also changed,hence patient number has also changed from 44 to74.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top